Oncology
Collaboration with SGC-Oxford
In October 2015 C4X Discovery announced that it had entered into a research collaboration with the University of Oxford’s Structural Genomics Consortium department (SGC-Oxford). SGC-Oxford is part of the Nuffield Department of Clinical Medicine and consists of around 100 scientists who collaborate widely with major pharmaceutical companies and the worldwide academic network, including several other University Departments, such as the Kennedy Institute of Rheumatology, the Botnar Research Centre and the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS). These scientists combine world-class expertise in therapeutic target validation, protein expression, assay development and protein structural information.
 
 
Under the terms of the collaboration C4XD has access to structural, biological and therapeutic information that SGC-Oxford holds in relation to various therapeutic targets and related assays, as well as initial ‘hit’ molecules that SGC-Oxford has identified against these targets. C4X Discovery’s expertise in drug design will be used to complement SGC-Oxford’s expertise in X-ray crystallography, screening and chemical biology in the identification of new and improved hit molecules against the SGC-Oxford targets. The first target chosen to collaborate on is an epigenetic target potentially useful for the treatment of cancer, such as cancers of the breast, prostate, lung and head and neck.

Improvements made to SGC-Oxford’s existing hit molecules will be the exclusive property of SGC-Oxford, who will make them freely available in line with SGC-Oxford policy, while new compounds independently identified by C4X Discovery will belong to the Company.